6-Hydroxydopamine (6-OHDA) lesions are being used in the mouse for basic research on Parkinson's disease and L-DOPA-induced dyskinesia. We set out to compare unilateral lesion models produced by intrastriatal or intramesencephalic injections of a fixed 6-OHDA concentration (3.2 μg/μl) in C57BL/6 mice. In the first experiment, toxin injections were performed either at two striatal coordinates (1 or 2 μl per site, termed "striatum 2 × 1 μl " and "striatum 2 × 2 μl " models), in the medial forebrain bundle (MFB), or in the substantia nigra pars compacta (SN) (1 μl per site). All the four lesion models produced significant forelimb use asymmetry, but spontaneous turning asymmetry only occurred in the MFB and striatum 2 × 2 μl models. After the behavioral studies, the induction of phosphorylated extracellular signal-regulated kinases 1 and 2 (pERK1/2) by acute L-DOPA (30 mg/kg) was used as a marker of post-synaptic supersensitivity. Striatal pERK1/2 expression was sparse in the SN and striatum 2 × 1 μl groups, but pronounced in the striatum 2 × 2 μl and MFB-lesioned mice. In further experiments, mice with MFB and striatal 2 × 2 μl lesions were used to compare behavioral and molecular responses to chronic L-DOPA treatment (12 days at 3 and 6 mg/kg/day). Maximally severe abnormal involuntary movements (AIMs) occurred in all MFB-lesioned mice, whereas only 35% of the mice with striatal lesions developed dyskinesia. Striatal tissue levels of dopamine were significantly lower in the dyskinetic animals (both MFB and striatum 2 × 2 μl groups) in comparison with the non-dyskinetic ones. Noradrenaline levels were significantly reduced only in MFB lesioned animals and did not differ among the dyskinetic and non-dyskinetic cases with striatal lesions. In all groups, the L-DOPA-induced AIM scores correlated closely with the number of cells immunoreactive for tyrosine hydroxylase or FosB/ΔFosB in the striatum. In conclusion, among the four lesion procedures examined here, only the MFB and striatum 2 × 2 μl models yielded a degree of dopamine denervation sufficient to produce spontaneous postural asymmetry and molecular supersensitivity to L-DOPA. Both lesion models are suitable to reproduce L-DOPA-induced dyskinesia, although only MFB lesions yield a pronounced and widespread expression of post-synaptic supersensitivity markers in the striatum.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by a loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNpc) projecting to the striatum, leading to bradykinesia, tremor, rigidity and postural abnormalities (Fahn, 2003) . The mechanisms underlying this neuronal degeneration are still unclear and no current treatment can inhibit the progression of the disease. The signs and symptoms of PD are dramatically ameliorated by the DA precursor, L-DOPA. However, the vast majority of PD patients treated with L-DOPA develop dyskinesia (abnormal involuntary movement, AIMs) and motor fluctuations (Ahlskog and Muenter, 2001 ). L-DOPA-induced dyskinesia is believed to result from fluctuations in central levels of DA, causing aberrant plasticity in dopaminoceptive brain structures, among which the striatum plays a crucial role (reviewed in Bezard et al., 2001; Carta et al., 2008; Cenci and Konradi, 2010; Chase, 1998) . Animal models of PD and L-DOPA-induced dyskinesia are essential to investigate pathophysiological mechanisms and identify new potential therapies. Parkinsonian-like motor features and L-DOPA-induced dyskinesia can be reproduced in mammalian species sustaining neurotoxic lesions of nigral DA neurons (reviewed in Cenci et al., 2002; Fox and Brotchie, 2010) . Unilateral injections of 6-hydroxydopamine (6-OHDA) in the nigrostriatal pathway have been widely used and extensively characterized in rats (reviewed in Neurobiology of Disease 42 (2011) 327-340 
